Key result
Intravenous verapamil had minimal effects on conduction times and refractory periods of the anomalous bypass, but terminated reciprocal supraventricular tachycardia in all 6 patients tested.
Why the study?
Does intravenous verapamil alter electrophysiological properties of the anomalous bypass and terminate supraventricular tachycardia in patients with Wolff-Parkinson-White syndrome?
Population
8 patients with Wolff-Parkinson-White syndrome
Design
Case_series
Authors
Loading...
May support verapamil for acute SVT termination in WPW; hypothesis-generating from case reports only.
Does intravenous verapamil alter electrophysiological properties of the anomalous bypass and terminate supraventricular tachycardia in patients with Wolff-Parkinson-White syndrome?
Intravenous verapamil effectively terminates reciprocal supraventricular tachycardia in WPW syndrome despite having minimal or variable effects on the electrophysiological properties of the anomalous bypass itself.
Spurrell et al. (1974) studied Wolff-Parkinson-White syndrome (n=8). Verapamil was evaluated on Conduction times and refractory periods of the anomalous bypass. Intravenous verapamil had minimal effects on conduction times and refractory periods of the anomalous bypass, but terminated reciprocal supraventricular tachycardia in all 6 patients tested.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: